Jade Biosciences, Inc.(JBIO)Earnings, Financials & Key Ratios
JBIO•NASDAQ
$22.00
Price updated Jun 27, 2026
AboutJade Biosciences, Inc. is a biotechnology company focused on developing best-in-class therapies to address critical unmet needs in autoimmune diseases. Their lead asset, JADE-001, targets the anti-A PRoliferation-Inducing Ligand (APRIL) pathway for the treatment of immunoglobulin A (IgA) nephropathy. JADE-001 is anticipated to enter clinical trials in the second half of 2025, with initial data expected in the first half of 2026. The company's pipeline also includes two preclinical antibody programs, JADE-002 and JADE-003.Show more
- Revenue$0
- EBITDA-$114M-52.8%
- Net Income-$127M-83.0%
- EPS (Diluted)-4.06+95.2%
- ROE-62.31%+16.8%
JBIO Price & Volume
Jade Biosciences, Inc. (JBIO) stock price & volume — 10-year historical chart
Loading chart...
Accelerated Clinical Spending Pressures Liquidity Runway
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial Position:Vulnerable
Cash Flow:Burning
Primary Risk:Clinical trial execution failure
"Jade Biosciences is currently in a high-risk, pre-revenue development phase characterized by aggressive R&D spending to advance its JADE-001 clinical program. While the company maintains a clean balance sheet with negligible debt, the rapid depletion of cash reserves from $88.4M in 2025Q4 to $55.1M in 2026Q1 suggests an urgent need for future capital raises. Investors should monitor the upcoming clinical data readouts, as the firm's valuation is almost entirely tied to intangible intellectual property with minimal tangible assets like its $847.0K in net PPE."
Verdict Logic
the company's current cash burn rate of over $40M per quarter relative to its $55.1M cash balance suggests significant near-term dilution risk for existing shareholders.
JBIO Growth Metrics
Jade Biosciences, Inc. (JBIO) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-86.04%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM95.61%
Return on Capital
10 Years-94.67%
5 Years-53.15%
3 Years-68.04%
Last Year-55.42%
JBIO Recent Earnings
Jade Biosciences, Inc. (JBIO) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 3/6 qtrs (50%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$0.57-9.6%
$0.52
Rev
—
—
Q2 2026
Mar 6, 2026Metric
Actual
Est
EPS
$0.11+75.6%
$0.45
Rev
—
—
Q4 2025
Nov 13, 2025Metric
Actual
Est
EPS
$0.48+15.8%
$0.57
Rev
—
—
Q3 2025
Aug 13, 2025Metric
Actual
Est
EPS
$0.86-100.0%
$0.43
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.57vs $0.52-9.6% | — |
| Q2 2026 | Mar 6, 2026 | $0.11vs $0.45+75.6% | — |
| Q4 2025 | Nov 13, 2025 | $0.48vs $0.57+15.8% | — |
| Q3 2025 | Aug 13, 2025 | $0.86vs $0.43-100.0% | — |
Based on last 6 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Jade Biosciences, Inc. (JBIO)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $22.00 | $717.77M | -5.42 | — | — | -62.31% | — | |
| $372.25 | $10.97B | 54.42 | 33.94% | 53.92% | 19.25% | — | |
| $31.00 | $3.12B | -9.42 | -4.26% | -156.36% | -68.97% | — | |
| $38.85 | $7.98B | -14.03 | — | — | -68.16% | — | |
| $27.00 | $3.38B | -207.69 | 91.34% | -0.57% | -1.41% | — | |
| $21.53 | $2.22B | -20.70 | 20.6% | -67.85% | -23.43% | — |
Compare JBIO vs Peers
Jade Biosciences, Inc. (JBIO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when JBIO posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
JBIO Frequently Asked Questions
Jade Biosciences, Inc. (JBIO) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is JBIO profitable?
Jade Biosciences, Inc. (JBIO) reported a net loss of $129.6M for fiscal year 2025.
Dividend & Returns
What is JBIO's return on equity?
Jade Biosciences, Inc. (JBIO) has a return on equity (ROE) of -62.3%. Negative ROE indicates the company is unprofitable.
What is Jade Biosciences, Inc.'s free cash flow?
Jade Biosciences, Inc. (JBIO) had negative free cash flow of $116.6M in fiscal year 2025, likely due to heavy capital investments.